SCHEDULE: Balyasny Asset Management Takes 8.04% Stake in Arcturus Therapeutics

Balyasny Asset Management L.P. and its affiliates have disclosed a beneficial ownership of 8.04% in Arcturus Therapeutics Holdings Inc., holding 2,183,985 shares.

Summary

• Balyasny Asset Management L.P., along with BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny (collectively, the "Reporting Persons"), have reported beneficial ownership in Arcturus Therapeutics Holdings Inc.
• The Reporting Persons beneficially own an aggregate of 2,183,985 shares of Arcturus Therapeutics Holdings Inc. common stock.
• This ownership represents 8.04% of the total class of common stock, calculated based on the issuer's reported outstanding shares as of August 8, 2025.
• The shares are held directly by Atlas Diversified Master Fund, Ltd. ("ADMF"), an investment management client of Balyasny Asset Management L.P.
• The Reporting Persons exercise sole voting and dispositive power over all 2,183,985 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant 8.04% stake by a reputable institutional investor like Balyasny Asset Management is generally a positive signal, indicating confidence in the company's value or future prospects. The filing explicitly states the acquisition was in the ordinary course of business and not for control, suggesting a strategic investment.

Positives

• A significant institutional investor, Balyasny Asset Management L.P., has taken an 8.04% stake in Arcturus Therapeutics Holdings Inc., which can be viewed as a vote of confidence in the company's future prospects.
• The investment is stated to be in the ordinary course of business, suggesting a strategic investment rather than an activist play.

Future Outlook

NA

Industry Context

The disclosure of a significant stake by a prominent asset manager like Balyasny Asset Management in a biotechnology company like Arcturus Therapeutics Holdings Inc. often signals institutional interest in the sector or specific company's pipeline and market position. This could reflect a broader trend of investment in innovative pharmaceutical or mRNA technology companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially influence stock price positively due to perceived validation from a major fund.
• Company Management: Awareness of a large institutional holder may influence strategic decisions, though the filing states the stake is not for control.

Key Dates

Recommendation

The disclosure of Balyasny Asset Management's 8.04% beneficial ownership in Arcturus Therapeutics Holdings Inc. is a positive indicator, suggesting institutional confidence in the company. However, this Schedule 13G filing provides no financial or operational details to warrant a stronger 'buy' recommendation. Investors should consider this as a favorable signal but conduct further due diligence on the company's fundamentals before making investment decisions.

Keywords

Arcturus Therapeutics, Balyasny Asset Management, Institutional Ownership, Common Stock, SEC Filing, Schedule 13G, Biotechnology, Investment, Shareholder